These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 19781924)
1. Mechanism of subendocardial cell proliferation in the rat and relevance for understanding drug-induced valvular heart disease in humans. Fielden MR; Hassani M; Uppal H; Day-Lollini P; Button D; Martin RS; Garrido R; Liu X; Kolaja KL Exp Toxicol Pathol; 2010 Nov; 62(6):607-13. PubMed ID: 19781924 [TBL] [Abstract][Full Text] [Related]
2. 5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Elangbam CS; Job LE; Zadrozny LM; Barton JC; Yoon LW; Gates LD; Slocum N Exp Toxicol Pathol; 2008 Aug; 60(4-5):253-62. PubMed ID: 18511249 [TBL] [Abstract][Full Text] [Related]
3. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Fitzgerald LW; Burn TC; Brown BS; Patterson JP; Corjay MH; Valentine PA; Sun JH; Link JR; Abbaszade I; Hollis JM; Largent BL; Hartig PR; Hollis GF; Meunier PC; Robichaud AJ; Robertson DW Mol Pharmacol; 2000 Jan; 57(1):75-81. PubMed ID: 10617681 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in the heart valves of Sprague-Dawley rats with spontaneous mitral valvulopathy--a possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats? Elangbam CS; Wehe JG; Barton JC; Krull DL; Nyska A; Crabbs T; Kissling GE Exp Toxicol Pathol; 2006 Nov; 58(2-3):89-99. PubMed ID: 16996724 [TBL] [Abstract][Full Text] [Related]
16. Dose dependency and reversibility of serotonin-induced valvular heart disease in rats. Droogmans S; Roosens B; Cosyns B; Degaillier C; Hernot S; Weytjens C; Garbar C; Caveliers V; Pipeleers-Marichal M; Franken PR; Bossuyt A; Schoors D; Lahoutte T; Van Camp G Cardiovasc Toxicol; 2009 Sep; 9(3):134-41. PubMed ID: 19609730 [TBL] [Abstract][Full Text] [Related]
17. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Kim JY; Chung EJ; Park SW; Lee WY Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692 [TBL] [Abstract][Full Text] [Related]
18. Regulatory Forum Review*: Utility of in Vitro Secondary Pharmacology Data to Assess Risk of Drug-induced Valvular Heart Disease in Humans: Regulatory Considerations. Papoian T; Jagadeesh G; Saulnier M; Simpson N; Ravindran A; Yang B; Laniyonu AA; Khan I; Szarfman A Toxicol Pathol; 2017 Apr; 45(3):381-388. PubMed ID: 28421966 [TBL] [Abstract][Full Text] [Related]
19. Bromocriptine use and the risk of valvular heart disease. Tan LC; Ng KK; Au WL; Lee RK; Chan YH; Tan NC Mov Disord; 2009 Feb; 24(3):344-9. PubMed ID: 18989898 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological evidence for a functional serotonin-2B receptor in a human uterine smooth muscle cell line. Kelly CR; Sharif NA J Pharmacol Exp Ther; 2006 Jun; 317(3):1254-61. PubMed ID: 16517693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]